|
Objective: To observe the efficacy of intravitreal injection of Avastin to treat macular edema (ME). Methods: binocular indirect ophthalmoscope, optical coherence tomography (OCT) or (and) fundus fluorescein angiography (FFA) checks diagnosed with macular edema in patients with a total of 69 cases of 76, divided according to etiology of central retinal vein occlusion (CRVO) , branch retinal vein occlusion (BRVO) and diabetic retinopathy (DR) line intravitreal injection of Avastin 1.25mg/0.05ml. Followed up for 2-13 months, visual acuity, intraocular pressure, lens, fundus, FFA observed macular edema and capillary leakage and the OCT examination macular edema and central macular retinal thickness (CMT). Results: The vision of the statistical results showed that the three groups of patients before treatment and after treatment, 1w, 1m, 2m, 3m four time points BCVA LogMAR values ??compared are significant differences that significantly improved vision after treatment. CRVO due after the treatment of ME patients at all time points between LogMAR no significant difference; BRVO due to ME patients 1m after treatment after treatment, 2m, 3m BCVA LogMAR value compared different t values ??were - 2.282, -3.000, P values ??were 0.031,0.006, to that treatment 1m up to the best vision after treatment, 2m, 3m declined; 1 m 1 w DME patients after treatment and after treatment BCVA LogMAR values 0.57 ± 0.32,0.54 ± 0.27, there is a statistically significant difference (P <0.05) between the two, that is, after treatment 1m vision better than 1w vision after treatment, and the treatment of 1m, 2m, 3m among the more significant difference. CMT's statistics showed that the three groups of patients after treatment 1m, 2m, 3m central macular retinal thickness compared with treatment before there is a significant difference, and that is the center of the macula retinal thickness than before treatment was significantly thinner macular edema improved significantly. 1m and treatment of CRVO due to ME patients with 3m CMT were (337.57 ± 35.851) μm (375.11 ± 23.219) μm, compared to a significant difference (P <0.05); BRVO due to ME patients and patients with DME treatment was no significant difference between the value of each time point after CMT. OCT image display treatment of macular retinal thickness was significantly thinner. FFA showed that treatment of macular fluorescein leakage was significantly reduced macular edema subsided. Statistics showed IOP, BRVO ME patients and DME patients before and after treatment at each time point IOP caused no statistically significant difference (P> 0.05) between 1w CRVO patients after treatment than before treatment intraocular pressure, and there is a significant difference (P <0.05). 11 two months later the vision again fell, and review of the FFA the results show macular edema recurred to give intravitreal Avastin same dose repeated injections, one month after surgery visual acuity and macular edema. 3 after treatment 1d small pieces of corneal epithelial exfoliation, 9 after treatment at the injection site, small pieces of subconjunctival hemorrhage severely elevated intraocular pressure, cataract, endophthalmitis, retinal detachment and other serious complications occur. Conclusion: Intravitreal injection Avastin effective treatment of CRVO, BRVO DR due to ME, some patients required repeat injection to maintain efficacy. The study found no drug-related serious ocular and systemic adverse reactions.
|